Bonesupport is a Swedish firm developing injectable bioceramic bone substitute products to treat bone voids caused by trauma, infection, disease or related surgery.
One of the group’s pipeline projects is centred around ‘Cerament’, a material capable of enhancing bone growth. Research into Cerament has been awarded SEK 8 million in external funding from Sweden’s innovation agency Vinnova.
The project will be conducted by an Indo-Swedish university research group.
The research will evaluate a combination of biphasic ceramics, bone active molecules and the body’s own cells to regenerate bone and improve mechanical strength in osteoporotic subjects.
One of the goals is to assess the capability of Cerament G, a bone graft substitute that elutes the antibiotic gentamicin, to deliver a combination of bone morphogenic protein-2 to induce bone formation and zoledronic acid to decrease secondary bone resorption.
Richard Davies, CEO of Bonesupport said: “If successful, this project will help us accelerate the development of products in our pipeline which is focused on delivering improved treatment options for osteoporotic fractures. We are confident that a new Cerament product which can deliver agents that enhance bone growth will be very attractive commercially.”
